THE ROLE OF NEW MARKERS IN THE DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER
https://doi.org/10.24884/1561-6274-2017-21-4-84-89
Abstract
AIM: to determine the significance of [-2]proPSA and prostate health index for the diagnostics of prostate diseases in patients with PSA level in blood plasma less than 4 ng/ml. PATIENTS AND METHODS: 148 men were examined in the urology clinic of Pavlov First Saint Petersburg State Medical University for the exclusion of prostate cancer (PCa). The inclusion criteria were: the level of total PSA in blood plasma less than 4 ng/ml, the presence of changes in the prostate during digital rectal examination, the detection of hypoechoic sites according to transabdominal ultrasound examination of the prostate or a decrease in the ratio of free and total PSA in blood plasma less than 15%. For all the patients the level of [-2]proPSA was assessed, its percentage to total PSA and the prostate health index were calculated. Based on the results of the biopsy, all patients were divided into 3 groups. Patients with histopathomorphologically verified benign prostatic hyperplasia (BPH) were included in the first group (83 patients), in the second group (14 patients) - with prostatic intraepithelial neoplasia (PIN), in the third (51 patients) - patients who had focal atypia and/or adenocarcinoma of the prostate. Clinical and laboratory parameters were compared between the abovementioned groups. RESULTS: Prostate health index was found to be the most significant factor of difference comparing patients with BPH and PCa, as well as in the presence of PIN and PCa (p<0.001 for both), while a statistically significant difference in this indicator was not obtained comparing BPH and PIN patients. CONCLUSION: Prostate health index showed the greatest prognostic value in the diagnostics of prostate diseases in patients with PSA level in blood plasma less than 4 ng/ml.
About the Authors
V. D. Yakovlev
First Pavlov St.-Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD student
197022 Russia, St-Petersburg, L. Tolstoy st., 17, build. 54 First Pavlov St.-Petersburg State Medical University, Department of urology with the course of urology and clinic. Phone: (812) 338 6918
А. S. Al-Shukri
First Pavlov St.-Petersburg State Medical University
Russian Federation
Russian Federation
Prof., MD, PhD
197022, Russia, St-Petersburg, L. Tolstoy st., 17, build. 54 First Pavlov St.-Petersburg State Medical University Department of urology with the course of urology and clinic Phone: (812) 338 6918
М. А. Rybalov
First Pavlov St.-Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD, senior researcher
197022 Russia, St-Petersburg, L. Tolstoy st., 17, build. 54 First Pavlov St.-Petersburg State Medical University Department of urology with the course of urology and clinic Phone: (812) 338 6918
S. Yu. Borovets
First Pavlov St.-Petersburg State Medical University
Russian Federation
Russian Federation
Prof., MD, PhD
197022 Russia, St-Petersburg, L. Tolstoy st., 17, build. 54 First Pavlov St.-Petersburg State Medical University Department of urology with the course of urology and clinic Phone: (812) 338 6918
A. G. Boriskin
First Pavlov St.-Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD
197022 Russia, St-Petersburg, L. Tolstoy st., 17, build. 54 First Pavlov St.-Petersburg State Medical University Department of urology with the course of urology and clinic Phone: (812) 338 6918
E. S. Nevirovich
First Pavlov St.-Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD
197022 Russia, St-Petersburg, L. Tolstoy st., 17, build. 54 First Pavlov St.-Petersburg State Medical University Department of urology with the course of urology and clinic. Phone: (812) 338-69-18
References
1. Basso D, Fogar P, Piva MG et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology 2000;55(5):710–715
2. Stenman UH, Leinonen J, Zhang WM et al. The clinical importance of free prostate–specific antigen (PSA). Curr Opin Urol 1998;8(5):393-399
3. Лоран ОБ, Пушкарь ДЮ, Степанов ВП, Крохотина ЛВ. Дифференциальная диагностика опухолей предстательной железы с помощью определения уровня простатспецифического антигена сыворотки крови. М., 2000;17 [Loran OB, Pushkar DYu, Stepanov VP, Krohotina LV. Differentsialnaya diagnostika opuholey predstatelnoy zhelezyi s pomoschyu opredeleniya urovnya prostatspetsificheskogo antigena syivorotki krovi. M., 2000;17]
4. Лоран ОБ, Пушкарь ДЮ, Франк ГА. Простатспецифический антиген и морфологическая характеристика рака предстательной железы: Руководство для врачей. МЕДпресс, М.,1999;144. [Loran OB, Pushkar DYu, Frank GA. Prostatspetsificheskiy antigen i morfologicheskaya harakteristika raka predstatelnoy zhelezyi: Rukovodstvo dlya vrachey. MEDpress, M.,1999;144.]
5. Пожарисский КМ, Воробьев АВ. Патоморфологическая характеристика и особенности карциномы предстательной железы. Значение простатической интраэпителиальной неоплазии. Практ онкол 2001;2(6): 17-23 [Pozharisskiy KM, Vorobev AV. Patomorfologicheskaya harakteristika i osobennosti kartsinomyi predstatelnoy zhelezyi. Znachenie prostaticheskoy intraepitelialnoy neoplazii. Prakt onkol 2001;2(6): 17-23]
6. Абрамова ОА, Абрамов ВА, Бондаренко ТГ. Результаты лабораторного скрининга на простатспецифический антиген методом иммуноферментного анализа в г. Амурске. Здравоохранение Дал Востока 2014;4:73-75 [Abramova OA, Abramov VA, Bondarenko TG. Rezultatyi laboratornogo skrininga na prostatspetsificheskiy antigen metodom immunofermentnogo analiza v g. Amurske. Zdravoohranenie Dal Vostoka 2014;4:73-75]
7. . Брезгина МФ, Скворцов ВВ, Зайцев ВГ. Скрининг рака предстательной железы с использованием теста на простатспецифический антиген. Мед сестра 2015;1:20-22 [Brezgina MF, Skvortsov VV, Zaytsev VG. Skrining raka predstatelnoy zhelezyi s ispolzovaniem testa na prostatspetsificheskiy antigen. Med sestra 2015;1:20-22]
8. Bryant RJ, Lilja H. Emerging PSA-based tests to improve screening. Urol Clin North Am 2014;41(2):267-276. doi: 10.1016/j.ucl.2014.01.003
9. Тимофеева АВ, Мальковская ЕВ, Бурмистрова АЛ. Оценка диагностической значимости общего простат-специфического антигена в качестве маркера развития опухолей предстательной железы. Пробл совр науки и образования 2015; 6:30-33 [Timofeeva AV, Malkovskaya EV, Burmistrova AL. Otsenka diagnosticheskoy znachimosti obschego prostat-spetsificheskogo antigena v kachestve markera razvitiya opuholey predstatelnoy zhelezyi. Probl sovr nauki i obrazovaniya 2015;6:30-33]
10. . Carlsson S, Assel M, Sjoberg D et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ 2014; 348:g2296. doi: 10.1136/bmj.g2296
11. . Le BV, Griffin CR, Loeb S et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010;183(4):1355-1359. doi: 10.1016/j.juro.2009.12.056
12. . Mikolajczyk SD, Marker KM, Millar LS et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61(18):6958-6963
13. . Ружанская АВ, Евгина СА, Скибо ИИ. Практическое использование маркера -2проПСА и индекса здоровья простаты phi в диагностике рака предстательной железы. Клинич лаб диагностика 2014;1:4-8 [Ruzhanskaya AV, Evgina SA, Skibo II. Prakticheskoe ispolzovanie markera -2proPSA i indeksa zdorovya prostatyi phi v diagnostike raka predstatelnoy zhelezyi. Klinich lab diagnostika 2014;1:4-8]
14. . Catalona WJ, Partin AW, Sanda MG et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185(5):1650-1655. doi: 10.1016/j.juro.2010.12.032
15. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-916. DOI: 10.1056/NEJM198710083171501
16. . Filella X, Foj L, Augé JM et al. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin Chem Lab Med 2014; 52(9):1347-1355. doi: 10.1515/cclm-2014-0027
17. . Lazzeri M, Haese A, de la Taille A et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013;63(6):986-994. doi: 10.1016/j.eururo.2013.01.011
18. Mearini L, Ferri C, Lazzeri M et al. Evaluation of prostatespecific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Urol Int 2014;93(2):135-145. doi: 10.1159/000356240
19. Sokoll LJ, Chan DW, Mikolajczyk SD et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5 – 4.0 ng/ml total PSA range: preliminary analysis. Urology 2003; 61(2): 274-276
Review
For citations:
Yakovlev V.D., Al-Shukri А.S., Rybalov М.А., Borovets S.Yu., Boriskin A.G., Nevirovich E.S. THE ROLE OF NEW MARKERS IN THE DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER. Nephrology (Saint-Petersburg). 2017;21(4):84-89. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-4-84-89
Views:
965
Email this article 